Proof‐of‐concept study of anti‐Fel d 1 IgY antibodies in cat food using the MASK‐air® app

Background An innovation to better manage cat‐allergic patients utilises anti‐Fel d 1 IgY antibodies to neutralise Fel d 1 after its production by the cat. However, there is no published study showing its clinical efficacy in humans in a home setting. A longitudinal, open‐label, proof‐of‐concept stu...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Clinical and translational allergy Ročník 14; číslo 5; s. e12353 - n/a
Hlavní autori: Bousquet, Jean, Gherasim, Alina, Blay, Frédéric, Mathieu‐Dupas, Eve, Batot, Géraldine, Laune, Daniel, Sousa‐Pinto, Bernardo, Zuberbier, Torsten, Pham‐Thi, Nhân, Hofmann, Bernard, Urban‐Kraemer, Emilie, Nguyen‐Grosjean, Van‐Mai, Lustgarten, Véronique, Defrance, Catherine
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: England John Wiley & Sons, Inc 01.05.2024
John Wiley and Sons Inc
Wiley
Predmet:
Allergens
Allergies
Antibodies
anti‐Fel d 1 antibodies
Asthma
cat allergy
cat food
Cats
combined symptom‐medication score
conjunctivitis
Food
Hay fever
Immunotherapy
Original
Patients
Pollen
Questionnaires
Rhinitis
Variables
cat allergy
asthma
rhinitis
combined symptom‐medication score
conjunctivitis
cat food
anti‐Fel d 1 antibodies
ISSN:2045-7022, 2045-7022
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:Background An innovation to better manage cat‐allergic patients utilises anti‐Fel d 1 IgY antibodies to neutralise Fel d 1 after its production by the cat. However, there is no published study showing its clinical efficacy in humans in a home setting. A longitudinal, open‐label, proof‐of‐concept study was carried out to approach clinical efficacy of the cat food in cat‐allergic patients. Methods After a baseline evaluation, the cats ate only the cat food for the following 4 months. Daily evaluation of efficacy was performed for 2 weeks at baseline and after 1, 2 and 3 months of intervention for periods of 2 weeks. The MASK‐air app was used daily to assess symptoms, work productivity and medications. Results Of the 49 patients screened, 42 were followed up and 33 (78.5%) reported MASK‐air data at all 3 evaluation periods. The primary end point (visual analogue scale [VAS] for global allergy symptoms) was significantly improved (p < 0.0001). All symptoms (VAS nose, eye, and asthma), VAS work and the combined symptom‐medication score significantly improved after 1 month. The percentage of uncontrolled days (VAS>20/100) decreased from 64% at baseline to 35% at 1 month (p < 0.0001) and 14% at 3 months. A sensitivity analysis in patients with uncontrolled disease at baseline found similar results. Discussion A cat diet containing anti‐Fel d 1 antibodies was able to (i) show decreased allergic symptoms and related outcomes, (ii) inform the design and feasibility of future studies with a control arm and (iii) estimate the sample size of the study. Study registration number: clinicaltrials.gov: NCT05656482.
Bibliografia:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:2045-7022
2045-7022
DOI:10.1002/clt2.12353